Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05805176 · ClinicalTrials.gov registry record · NA

An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms

A NA study of ADHD, sponsored by Lumos Labs.

Active
Registry status
NA
Development phase
194
Enrollment target
5
Study locations

NCT05805176 is a NA study of ADHD that is active but no longer recruiting, run by Lumos Labs. The registered enrollment target is 194 participants, roughly in line with the 188-participant average among 75 other ADHD trials with a reported enrollment target. The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05805176, a NA study of ADHD, is active but no longer recruiting, sponsored by Lumos Labs.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
194 participants
Enrollment target
5
Study locations

Study Summary

The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).

Conditions Studied

Interventions

  • DEVICE ADHD Therapy

Study Locations (5)

Florida

  • CNS Healthcare of Jacksonville - Jacksonville
  • Accel Clinical Research Sites - Lakeland

Michigan

  • Rochester Center for Behavioral Medicine (RCBM) - Rochester Hills

Missouri

  • Midwest Research Group - Brentwood

New Jersey

  • Hassman Research Institute - Berlin

Trial Details

FieldValue
Enrollment Target 194 participants
Start Date 2023-04-15
Est. Completion 2025-06
Phase NA

Sponsor

Lumos Labs

9 total trials

What the Registry Record Tells You About NCT05805176

The ClinicalTrials.gov registry entry for NCT05805176 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 188-participant average among 75 other ADHD trials with a reported enrollment target. The listed sponsor is Lumos Labs, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which ADHD Therapy is the first listed.

NCT05805176 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Florida, Michigan, Missouri.

Frequently Asked Questions

What is clinical trial NCT05805176 about?

NCT05805176 is a clinical study titled "An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms". The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).

What is the current status of trial NCT05805176?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 194 participants. The study started on 2023-04-15. Estimated completion is 2025-06.

What conditions does trial NCT05805176 study?

This clinical trial studies the following conditions: ADHD.

What interventions are being tested in trial NCT05805176?

The interventions under investigation include: ADHD Therapy (DEVICE).

Who is sponsoring clinical trial NCT05805176?

This trial is sponsored by Lumos Labs, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05805176 being conducted?

This trial has 5 study locations across Florida, Michigan, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.